Focused On-demand Library for Norrin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q00604

UPID:

NDP_HUMAN

Alternative names:

Norrie disease protein; X-linked exudative vitreoretinopathy 2 protein

Alternative UPACC:

Q00604; B2R8K6; Q5JYH5

Background:

Norrin, also known as Norrie disease protein and X-linked exudative vitreoretinopathy 2 protein, is pivotal in activating the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptors. It plays a crucial role in retinal vascularization, signaling via beta-catenin stabilization and LEF/TCF-mediated transcriptional programs. Norrin acts alongside TSPAN12 to activate FZD4, indicating a Wnt-independent signaling pathway that also promotes beta-catenin accumulation. Its involvement in neural cell differentiation and proliferation, as well as neuroectodermal cell-cell interaction, underscores its biological significance.

Therapeutic significance:

Norrin's association with Norrie disease, characterized by early childhood blindness and potential mental disorders, and Vitreoretinopathy, exudative 2, highlights its therapeutic significance. Understanding Norrin's role in these diseases could lead to innovative treatments targeting the underlying genetic variants, offering hope for patients suffering from these retinal disorders.